Mediar Therapeutics
PrivateLast Round
Series B
Jan 7, 2026
Est. Valuation
$230.3M
Total Funding Raised
$181M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Mediar Therapeutics is a biotechnology company developing innovative antibody-based therapies aimed at halting and reversing fibrotic activity in chronic organ damage.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mediar Therapeutics Comparables
Compare Mediar Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Endeavor BioMedicines | 81% | |
| Certa Therapeutics | 81% | |
| AgomAb Therapeutics | 80% |
Mediar Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 7, 2026 | ||||
| Series A | Mar 15, 2023 | ||||
| Seed | Mar 17, 2021 |
Mediar Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Seed |
| Gimv | Series B, Series A |
| Asahi Kasei Pharma Ventures | Series B |
| Amplitude Ventures | Series B |
| Mass General Brigham Innovation | Series A, Seed |
| Intermediate Capital Group | Series B |
| Viva Biotech | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 108% MoM, reaching 4.3K.
- Jan 7, 2026
$76M round completed.
Recent news
Latest coverage and updates
- is_developingAug 7, 2026
Mediar Therapeutics, Inc. is developing treatments for fibro-inflammatory diseases on Aug 6th '26.
- partners_withAug 7, 2026
Mediar Therapeutics, Inc. partnered with Ono Pharmaceutical Co., Ltd. on Aug 7th '26.
- is_developingAug 7, 2026
Mediar Therapeutics, Inc. is developing novel antibody therapeutics on Aug 7th '26.
- is_developingAug 6, 2026
Mediar Therapeutics, Inc. is developing novel antibody therapeutics for fibro-inflammatory diseases on Aug 6th '26.
Mediar Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Mediar Therapeutics's valuation, stock price, and market status.
Is Mediar Therapeutics a public or private company?
Mediar Therapeutics is a private company.
What is the current stock price of Mediar Therapeutics?
Mediar Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Mediar Therapeutics worth (valuation)?
Valuation information for Mediar Therapeutics is not publicly available.
Can I buy Mediar Therapeutics stock?
Mediar Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Mediar Therapeutics's last funding round?
Mediar Therapeutics's most recent funding round was Series B on January 7, 2026.
Who are the main investors in Mediar Therapeutics?
Key investors in Mediar Therapeutics include Sofinnova Partners.
Will Mediar Therapeutics IPO soon?
No public IPO plans have been announced for Mediar Therapeutics.
How can I track Mediar Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Mediar Therapeutics's secondary market activity and sign up for updates.